High Evidence (L1-L2)
Candidates that may be prioritised for clinical evaluation
Criteria
| Level | Definition | Clinical meaning |
|---|---|---|
| L1 | Multiple Phase 3 RCTs / systematic reviews | Strong support; clinical use may be considered |
| L2 | Single RCT or multiple Phase 2 trials | Moderate support; validation trials can be designed |
L1 (13 drugs)
| Drug | Indications | Link |
|---|---|---|
| Aripiprazole | 10 | View report |
| Atorvastatin | 6 | View report |
| Celecoxib | 10 | View report |
| Docetaxel | 10 | View report |
| Insulin Aspart | 10 | View report |
| Insulin Degludec | 10 | View report |
| Insulin Detemir | 10 | View report |
| Insulin Glulisine | 10 | View report |
| Salmeterol | 7 | View report |
| Simvastatin | 8 | View report |
| Temozolomide | 2 | View report |
| Tiotropium | 10 | View report |
| Vilanterol | 10 | View report |
L2 (13 drugs)
| Drug | Indications | Link |
|---|---|---|
| Albendazole | 10 | View report |
| Betamethasone | 10 | View report |
| Bupropion | 10 | View report |
| Candesartan | 10 | View report |
| Clomipramine | 10 | View report |
| Hydrocortisone | 10 | View report |
| Latanoprost | 10 | View report |
| Moclobemide | 2 | View report |
| Montelukast | 10 | View report |
| Neomycin | 10 | View report |
| Prednisone | 10 | View report |
| Pseudoephedrine | 3 | View report |
| Zolpidem | 10 | View report |
Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.
Reviewed by: 藥提醒科技有限公司 (yao.care)